Achilles Therapeutics plc (NASDAQ:ACHL – Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 122,300 shares, a growth of 35.4% from the December 15th total of 90,300 shares. Approximately 0.3% of the company’s stock are short sold. Based on an average daily trading volume, of 169,400 shares, the days-to-cover ratio is presently 0.7 days.
Hedge Funds Weigh In On Achilles Therapeutics
An institutional investor recently raised its position in Achilles Therapeutics stock. BML Capital Management LLC raised its stake in shares of Achilles Therapeutics plc (NASDAQ:ACHL – Free Report) by 555.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,100,002 shares of the company’s stock after buying an additional 3,474,828 shares during the quarter. Achilles Therapeutics comprises about 2.5% of BML Capital Management LLC’s investment portfolio, making the stock its 11th biggest holding. BML Capital Management LLC owned about 9.98% of Achilles Therapeutics worth $4,182,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 56.38% of the company’s stock.
Achilles Therapeutics Price Performance
Shares of Achilles Therapeutics stock opened at $1.14 on Friday. Achilles Therapeutics has a 1 year low of $0.63 and a 1 year high of $1.76. The company has a 50-day moving average of $1.08 and a 200 day moving average of $0.94. The firm has a market cap of $46.85 million, a price-to-earnings ratio of -0.69 and a beta of 1.32.
Achilles Therapeutics Company Profile
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.
Further Reading
- Five stocks we like better than Achilles Therapeutics
- What is the Shanghai Stock Exchange Composite Index?
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- What Are the U.K. Market Holidays? How to Invest and Trade
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- What is a Death Cross in Stocks?
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
